To the authors' knowledge, the optimal frequency of monitoring after tyrosine kinase inhibitor (TKI) discontinuation in patients with chronic myeloid leukemia (CML) has not been established. Data regarding the discontinuation of second-generation TKIs used in first-line treatment or after the failure of first-line treatment with TKIs are limited. Herein, the authors report real-world experience with "reduced frequency" molecular monitoring in patients with CML in all phases who discontinued treatment with imatinib, dasatinib, or bosutinib. METHODS: The records of patients who discontinued TKIs were reviewed. Patients who discontinued TKIs were monitored prospectively on an intended schedule of monthly blood quantitative reverse transcriptase-polymerase chain reaction for BCR-ABL1 for 3 months, quarterly for 12 months, and every 6 months thereafter until loss of major molecular response (MMR). After loss of MMR, the TKI that previously was discontinued was reinitiated. RESULTS: Between January 2010 and September 2015, a total of 24 patients in chronic (21 patients), accelerated (2 patients), and lymphoid blast (1 patient) phase discontinued imatinib (16 patients), dasatinib (5 patients), or bosutinib (3 patients) used in the front-line treatment or beyond. Blood quantitative reverse transcriptase-polymerase chain reaction for BCR-ABL1 was performed 1.3 6 0.7 times within the first 3 months (24 patients) and 2.7 6 1.4 times in the following 12 months (18 patients). With a median follow-up of 36.5 months (range, 3.2-67.4 months), the probabilities of treatment-free remission at 1 year and 2 years were 65.7% (95% confidence interval, 55.8%-75.6%) and 59.7% (95% confidence interval, 49.1%-70.3%), respectively. Loss of MMR was observed in 9 patients at a median of 2.8 months (range, 1.8-14.2 months) after discontinuation of TKIs. CONCLUSIONS: With the limitations of a small sample size, the results of the current study demonstrate that less frequent monitoring of BCR-ABL1 does not appear to affect outcomes, and that discontinuation of TKIs used as first-line treatment or beyond after resistance or intolerance to first-line treatment appears feasible. Cancer 2017;123:2482-8.
INTRODUCTION
Tyrosine kinase inhibitors (TKIs) have dramatically improved the outcomes of patients with chronic phase (CP) chronic myeloid leukemia (CML) and led to a survival in responding patients that was reported to be comparable to that of agematched controls. 1 To our knowledge, the duration of TKI therapy is unknown, and the concept of a life-long treatment with these oral agents recently was challenged by several studies that demonstrated sustained treatment-free remissions (TFRs) in patients who discontinued imatinib (IM) after prolonged deep molecular remissions (DMRs). [2] [3] [4] [5] These discontinuations were safe because off-therapy disease progression to advanced phases have not been reported to date and rapid regains of lost MRs after the reinitiation of IM were consistently observed. To our knowledge, data regarding the discontinuation of second-generation TKIs used in first-line treatment or after failure of first-line treatment with TKIs are limited. 6 After discontinuation of IM, patients are monitored closely for the reappearance of BCR-ABL1 using quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR), and typically according to a schedule established by the multicenter Stop Imatinib (STIM) study. [2] [3] [4] [5] This intense molecular monitoring consists of blood qRT-PCR obtained monthly for 6 months to 12 months, every other month for 6 months to 12 months, and quarterly thereafter. To the best of our knowledge, the optimal frequency of molecular monitoring after discontinuation of TKIs has not been established to date, and the impact of the frequency of this monitoring on outcomes is unknown. We herein report the outcomes of a real-world experience with a "reduced frequency" molecular monitoring in patients with CML in all phases who discontinued IM, dasatinib (DAS), or bosutinib (BOS).
MATERIALS AND METHODS

Patients and Methods
The records of patients with CML who discontinued TKI therapy after achieving undetectable molecular residual disease (DMR) of at least 2 years for any reason were reviewed. CP, accelerated phase (AP), and blast phase (BP) were defined according to standard criteria. 7, 8 Epidemiological information, CML-specific characteristics (including the results of diagnostic blood and bone marrow), treatment, and response to therapy were extracted. Patients who discontinued TKIs were monitored prospectively on an intended institutional schedule of monthly qRT-PCR of the blood for BCR-ABL1 for 3 months, quarterly for 12 months, and every 6 months thereafter. This institutional schedule was selected before the availability of the STIM study monitoring schedule, and was based on the assumption that disease recurrence would occur very soon after TKI discontinuation. When the rate of PCR recurrences was noted to be significantly lower than anticipated in the first 15 months, patients were reverted back to their every-6-months schedule. Previously described response criteria were used, 9 and DMR was defined as undetectable levels of BCR-ABL1 transcript by qRT-PCR with a sensitivity of at least 0.0063% (international scale, with ABL used as the control gene). Before 2007, a total of 3 patients were monitored using qualitative PCR for BCR-ABL1, and a "negative" result was considered as DMR. Molecular recurrence was defined as the loss of major molecular response (MMR) with a BCR-ABL1 transcript level >0.1% confirmed on 2 consecutive qRT-PCRs repeated within 4 weeks. 10 After loss of MMR, the same TKI that previously was discontinued was reinitiated and the same monitoring schedule was applied. This retrospective study was approved by the Emory University Institutional Review Board.
Statistical Analysis
The probability of TFR was estimated using the KaplanMeier method, and was calculated as the time from the first day of discontinuation of TKIs to the date of the first documentation of loss of MMR or last follow-up.
The Fisher exact test and the chi-square test were used to compare categorical variables, and the Mann-Whitney U test was used for continuous variables. Univariate analysis for identifying factors associated with loss of MMR was performed using the log-rank test. P values <.05 were considered to be statistically significant and all P values corresponded to 2-sided significance tests. The SPSS statistical program (version 22.0; IBM Corporation, Armonk, NY) was used for all calculations.
RESULTS
Patient Characteristics
Between January 2010 and September 2015, a total of 24 patients with CML in DMR discontinued treatment with TKIs. Patient characteristics are summarized in Table 1 . The median age of the patients was 56.7 years (range, 19.9-81.5 years); 21 patients had CP, 2 had AP, and 1 had lymphoid BP. Only 1 patient received interferon before treatment with a TKI. The patient with lymphoid BP disease was diagnosed in CP, transformed to lymphoid BP while receiving IM, had no detectable ABL1 kinase domain mutation, and experienced a transient response to cytotoxic chemotherapy using a combination of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose cytarabine and methotrexate. This patient achieved DMR with DAS, switched to BOS due to DAS intolerance, and maintained DMR while receiving BOS. 11 Reasons for TKI discontinuation were patient request (15 patients), chronic adverse events with TKIs (6 patients), and request to withdraw from TKI therapy while planning for pregnancy (3 patients). Sixteen patients discontinued IM when given as front-line (15 patients) or fourth-line treatment after intolerance to nilotinib, DAS, and BOS (1 patient). Five patients discontinued DAS administered as first-line (1 patient) or second-line treatment after IM resistance (2 patients) or IM intolerance (2 patients). Three patients discontinued BOS administered as second-line treatment after IM intolerance (2 patients) or third-line treatment after IM resistance and DAS intolerance (1 patient). The time from diagnosis to TKI discontinuation was 79.6 months (range, 38.4-186.0 months), and the median exposure to TKIs was 77.0 months (range, 38.4-168.1 months). The duration of DMR before TKI discontinuation was 49.9 months (range, 28.7-156.5 months), during which time 13 patients experienced a median of 2 transient detectable BCR-ABL1 transcripts (range, 1-5 transcripts) below MMR levels. Monitoring After TKI Discontinuation
The number of qRT-PCRs performed in the first 3, 6, 12, and 24 months were 1.3 6 0.7, 2.2 6 1.2, 3.3 6 1.2, and 6.1 6 1.5 in 24, 18, 15, and 11 evaluable patients, respectively. The intended monthly qRT-PCR was performed in 2 of 24 patients (8.3%) in the first 3 months, quarterly in 5 of 18 patients (27.8%) in the following 12 months, and biannually in all eligible patients (9 patients) beyond this point. The mean (6 standard deviation) numbers of qRT-PCRs performed during these 3 time periods are summarized in Figure 1 . Reasons for not obtaining qRTPCRs on the scheduled time points included scheduling errors, patient no-shows, and laboratory request processing errors. Overall, a total of 134 qRT-PCRs were performed among these 24 patients, which translates into a 45.3 person-years and a mean frequency of 3.0 qRTPCRs per year.
Outcomes After TKI Discontinuation
The median follow-up from the time TKI was discontinued was 36.5 months (range, 3.2-67.4 months) for the entire cohort. Overall, 15 patients (62.5%) did not experience loss of MMR. The probabilities of TFR at 1 year and 2 years were 65.7% (95% confidence interval, 55.8%-75.6%) and 59.7% (95% confidence interval, 49.1%-70.3%]), respectively (Fig. 2) . Four patients experienced a median of 2 detectable BCR-ABL1 (range, 1-3) below the level of MMR. Nine patients (37.5%) experienced loss of MMR at a median of 2.8 months (range, 1.8-14.2 months) after TKI discontinuation (Fig. 3) , and the median BCR/ABL1
IS at the time of molecular recurrence was 0.983 (range, 0.321-19.481). With the exception of 1 patient who experienced a loss of MMR at 14.2 months, all molecular recurrences occurred within the first 6 months.
Outcomes After Reinitiation of TKIs
All 9 patients who experienced loss of MMR reinitiated treatment with the TKI that was previously discontinued: IM (7 patients), DAS (1 patient [patient 4]), and BOS (1 patient [patient 3]). Response to the reinitiation of TKI was monitored with the same schedule as described above, and the number of qRT-PCRs performed in the first 3, 6, and 12 months were 1.1 6 0.6, 2.3 6 0.7, and 4.0 6 0.5, respectively. Response to the reinitiation of TKIs is depicted in Figure 3 : 5 patients regained DMR at a median of 3.8 months (range, 1.1-5.8 months) (patients 1-4 and 9), and 2 achieved MMR at 41.5 months (patient 5) and 7 months (patient 8). Two patients (patients 6 and 7) achieved complete cytogenetic remission (CCyR) but had not regained MMR at the time of last follow-up. All patients tolerated the reinitiation of the TKI well, with the exception of one patient who required a dose reduction of DAS due to grade 3 nonhematologic toxicity (according to the CTCAEv4.0) that occurred at doses that previously had been well tolerated. With the exception of 3 patients, TKIs were reinitiated promptly (within 1 month) after documented loss of MMR. Patient 6 refused to restart IM due to cardiac transplantation complications, lost a complete hematologic response 13 months later, remained in CP, and agreed to reinitiate IM after his cardiac transplantation rejection resolved. This patient had no detectable ABL kinase domain mutation, and achieved a CCyR 9 months after the reinitiation of IM. At the time of last follow-up (at 28 months), the patient demonstrated continuous CCyR and the blood qRT-PCR was 0.8%. Patient 7 lost MMR at 2 months after stopping BOS and shortly after becoming pregnant. This patient experienced a loss of CCyR and subsequent loss of complete hematologic response prepartum. The patient reinitiated BOS postpartum, 7 months after the loss of MMR, and achieved a transient CCyR 4 months later. She remained in CP and had no detectable ABL kinase domain mutation. This patient enrolled on a trial testing the combination of DAS with nivolumab. Patient 3 lost MMR at 14.2 months after stopping IM and was reluctant to restart IM due to prior intolerance. This patient previously achieved a DMR on a maximally tolerated dose of IM of 200 mg/day. The patient remained in CCyR with a qRT PCR <1.0% for 10 months, then agreed to restart IM when a transcript level was detected at 1.8%. This patient regained a sustained DMR 3.8 months later.
Sequencing of the ABL kinase domain detected the T306I mutation in patient 5, who was previously resistant to IM at a dose of 400 mg/day, intolerant to BOS, and achieved a DMR with IM at a dose of 600 mg/day. This patient lost MMR 3 months after stopping IM and regained MMR at 41.5 months after the reinitiation of IM at a dose of 600 mg/day.
Predictors of Loss of MMR
A comparison between patients who did and did not lose MMR after discontinuation of TKIs is summarized in Table 2. No significant differences were noted between the 2 groups with regard to age, sex, phase of the disease, prior interferon or chemotherapy exposure, duration of CML diagnosis, discontinuation of a TKI administered for resistant CML, or treatment with a newer generation TKI. Longer durations of TKI exposure (85.6 months vs 58.7 months; P 5.240) and DMR (57.0 months vs 46.6 months; P 5.491) were observed in patients who maintained MMR, but these differences did not reach statistical significance. The number of patients who experienced transient elevations of BCR-ABL1 transcripts levels below MMR before TKI discontinuation was comparable in both groups. Only 1 patient received interferon before the TKI. This patient remained in DMR for 67 months after discontinuation of IM. We also analyzed previously reported predictors for molecular recurrence after TKI discontinuation: age (55 years vs >55 years), sex, disease phase (CP vs AP and BC), exposure to a newer TKI (presence vs absence), TKI treatment duration (65 months vs >65 months), duration of DMR before TKI discontinuation (50 months vs >50 months), and episodes of transient elevation of BCR-ABL1 transcript during DMR (present vs absent). None of those variables was found to predict loss of MMR by univariate analysis. 
DISCUSSION
Given the remarkable survival of patients with CML in chronic phase who are treated with a TKI, it is not surprising that patients who discontinue TKIs are monitored extremely cautiously with very frequent BCR-ABL1 blood transcript levels. The intent of this close monitoring is to detect the reappearance of BCR-ABL1 early so that TKIs can be reinitiated immediately, MR reinstituted, and disease progression prevented. Fortunately, and across all studies, the prompt reinitiation of IM was found to consistently lead to a rapid regain of MRs (Table 3) . [2] [3] [4] [5] [6] 12, 13 With increasing experience and longer follow-up, the criteria for both discontinuing/restarting TKIs have evolved from MR 5 /loss of MR 5 to MR 4.5 /loss of MMR, and most recently MR 4 /loss of MMR. [2] [3] [4] 14 The application of these less strict criteria does not appear to have affected the rates of TFR nor the regain of MMR in subsequent IM discontinuation trials. 3, 4 To the best of our knowledge, the optimal frequency of monitoring after the discontinuation of TKIs is unknown, and it is unclear whether a less frequent monitoring schedule affects outcomes. In the current study, patients who discontinued TKIs were programmatically offered monitoring with monthly blood qRT-PCR for BCR-ABL1 for the first 3 months, quarterly for a year, and biannually thereafter. Because this monitoring was not part of a prospective clinical trial, the real-world compliance with this schedule was 8% in the first 3 months, 28% in the following 12 months, and 100% thereafter. Despite this reduced frequency, the outcomes of the current study patients do not appear to be any different from what has been previously reported (Table 3) . [2] [3] [4] [5] [6] 12, 13 Indeed, in the current series, the 1-year TFR rate was 65.7%, molecular recurrences were detected early after TKI discontinuation, all patients who promptly reinitiated TKIs regained MR, and no patient in this high-risk population experienced disease progression to the advanced phases. Among the 24 patients in the current study who discontinued TKIs, 2 had AP disease, 1 had BP disease, and 10 patients were exposed to second-generation TKIs, 4 of whom were resistant to previous TKIs. All patients with AP disease and the 7 of 10 patients exposed to newer TKIs, including 2 patients resistant to prior TKIs, had not lost MMR at the time of last follow-up (Table 2) . To our knowledge, the current study is the first to demonstrate that TKIs can be discontinued in this high-risk population. It is interesting to note that 3 patients reinitiated TKIs 7 months to 13 months after loss of MMR due to patient preferences or ongoing pregnancy. One regained DMR and the other 2 patients achieved CCyR after the reinitiation of TKI.
The current study was limited by a relatively small sample size, which may explain why no predictive factors for the loss of MMR were identified. In contrast with other studies, neither the duration of TKI exposure nor DMR was found to predict loss of MMR. It is interesting to note that also neither AP disease nor resistance to prior TKI was predictive of loss of MMR. Sokal score was not available for the majority of patients because patients were diagnosed at outside facilities and documentation was not sufficient to assign a Sokal score.
The results of the current study indicate that a less intensive blood molecular monitoring after discontinuation of TKIs appears to yield comparable outcomes to commonly used, more intense monitoring schedules. These results are provocative and currently are being validated in a prospective clinical trial (https://clinicaltrials. gov/show/NCT02730195). In addition, discontinuation of TKIs used as first-line treatment or beyond after resistance or intolerance to first-line treatment appears feasible.
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